PolTREG S.A.
Research PolTREG S.A. (PTG) on Bullrun: market cap PLN 137.37M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPTG
- ExchangeWAR
- CountryPoland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyPLN
- Market capPLN 137.37M
- Financial periodQ1 2026
- RevenuePLN 0
- Net income-PLN 6.78M
- Free cash flow-PLN 8.42M
Valuation Snapshot
latest market cap is PLN 137.37M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | PLN 0 | -PLN 26.00M | -PLN 28.42M | n/a | n/a | PLN 17.79M | PLN 7.62M | PLN 43.33M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | PLN 137.37M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 PLN.
About PolTREG S.A.
Poltreg S.A., a biotechnology company, researches and develops therapies for autoimmune diseases in Poland. Its product pipeline includes PTG-OO7 + Rituximab which is in phase II clinical trial to treat presymptomatic T1D; MOG CAR-Treg which is in phase I clinical trial for the treatment of multiple sclerosis, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is PolTREG S.A.'s market cap?
PolTREG S.A.'s market capitalization is PLN 137.37M.
What does PolTREG S.A. do?
Poltreg S.A., a biotechnology company, researches and develops therapies for autoimmune diseases in Poland. Its product pipeline includes PTG-OO7 + Rituximab which is in phase II clinical trial to treat presymptomatic T1D; MOG CAR-Treg which is in phase I clinical trial for the treatment of multiple sclerosis, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis; Multi-Edit/Allo MOG CAR-Treg which is in preclinical trial to treat multiple sclerosis, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis; and Antigen-specific T-regulatory cell (Tregs) which is in.